Supplement - Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

Supplement - Contents:
Plain Language Summary
Table SI. Comorbid conditions present in the medical history of 5% or more of the trial population
Table SII. Medical history of psychiatric comorbidities in the trial population
Table SIII. Use of concomitant prohibited medications/procedures and/or rescue medication
Fig S1. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Study design
Fig S2. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Patient disposition
Fig S3. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Baseline demographic characteristic subgroup analyses of responders at week 24
Fig S4. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Proportion of patients achieving ≥4-point reduction in WI-NRS from baseline over time
Fig S5. Prurigo nodularis. LIBERTY-PN PRIME/PRIME2 Pooled – Efficacy on patient-reported outcomes mean change from baseline to week 24